Literature DB >> 15339288

Designs for single- or multiple-agent phase I trials.

Mark R Conaway1, Stephanie Dunbar, Shyamal D Peddada.   

Abstract

Phase I trials of cytotoxic agents in oncology are usually dose-finding studies that involve a single cytotoxic agent. Many statistical methods have been proposed for these trials, all of which are based on the assumption of a monotonic dose-toxicity curve. For single-agent trials, this is a valid assumption. In many trials, however, investigators are interested in finding the maximally tolerated dose based on escalating multiple cytotoxic agents. When there are multiple agents, monotonicity of the dose-toxicity curve is not clearly defined. In this article we present a design for phase I trials in which the toxicity probabilities follow a partial order, meaning that there are pairs of treatments for which the ordering of the toxicity probabilities is not known at the start of the trial. We compare the new design to existing methods for simple orders and investigate the properties of the design for two partial orders.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15339288     DOI: 10.1111/j.0006-341X.2004.00215.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  36 in total

1.  Mass spectrometric determination of IgG subclass-specific glycosylation profiles in siblings discordant for myositis syndromes.

Authors:  Irina Perdivara; Shyamal D Peddada; Frederick W Miller; Kenneth B Tomer; Leesa J Deterding
Journal:  J Proteome Res       Date:  2011-06-08       Impact factor: 4.466

2.  Adaptive dose-finding based on safety and feasibility in early-phase clinical trials of adoptive cell immunotherapy.

Authors:  Nolan A Wages; Camilo E Fadul
Journal:  Clin Trials       Date:  2019-12-19       Impact factor: 2.486

3.  A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies.

Authors:  Akihiro Hirakawa; Nolan A Wages; Hiroyuki Sato; Shigeyuki Matsui
Journal:  Stat Med       Date:  2015-05-13       Impact factor: 2.373

4.  A Bayesian Dose-finding Design for Drug Combination Trials with Delayed Toxicities.

Authors:  Suyu Liu; Jing Ning
Journal:  Bayesian Anal       Date:  2013-09-09       Impact factor: 3.728

5.  BAYESIAN PHASE I/II ADAPTIVELY RANDOMIZED ONCOLOGY TRIALS WITH COMBINED DRUGS.

Authors:  Ying Yuan; Guosheng Yin
Journal:  Ann Appl Stat       Date:  2011-01-01       Impact factor: 2.083

Review 6.  Implementation of adaptive methods in early-phase clinical trials.

Authors:  Gina R Petroni; Nolan A Wages; Gautier Paux; Frédéric Dubois
Journal:  Stat Med       Date:  2016-02-29       Impact factor: 2.373

7.  A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials.

Authors:  Liangcai Zhang; Ying Yuan
Journal:  Stat Med       Date:  2016-08-31       Impact factor: 2.373

8.  A Generalized Continual Reassessment Method for Two-Agent Phase I Trials.

Authors:  Thomas M Braun; Nan Jia
Journal:  Stat Biopharm Res       Date:  2013-01-01       Impact factor: 1.452

9.  Dose--schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation.

Authors:  Yisheng Li; B Nebiyou Bekele; Yuan Ji; John D Cook
Journal:  Stat Med       Date:  2008-10-30       Impact factor: 2.373

10.  Designs for phase I trials in ordered groups.

Authors:  Mark R Conaway; Nolan A Wages
Journal:  Stat Med       Date:  2016-09-14       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.